MedTrace Logo

Research of Anatomo-functional Biomarkers in Schizophrenia

NCT03996122 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2019-06-24

No results posted yet for this study

Summary

To objectify UR biomarkers, we propose a longitudinal follow-up of resistant patients with schizophrenia, starting before the onset of clozapine and including a multimodal brain imaging assessment (T1 and T2 weighted sequences, DTI, ASL-Perfusion, fMRI- Rest) associated with clinical and biological monitoring. In order to correct the MRI signal of clozapine hemodynamic effects, we will develop a new MRI methodology based on the concomitant collection of physiological parameters (blood pressure, electrocardiogram and respiration).

Conditions

Interventions

OTHER

fMRI

3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Anaïs Vandevelde, MD · CHU of Caen, Esquirol

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-04
Primary Completion
2021-04-04
Completion
2021-10-04

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996122 on ClinicalTrials.gov